Skip to Content
  • Previous Rank
    12
  • Revenues ($M)
    $167,939.6
  • Revenue Percent Change
    9.7%
  • Profits ($M)
    $1,658.4
  • Profits Percent Change
    355.0%
  • Assets ($M)
    $37,669.8
  • Employees
    20,500

As go drug sales (and prices), so go the fortunes of drug distributors like Pennsylvania-based AmerisourceBergen, which acts as a middleman, delivering medicines from manufacturers to pharmacies and hospitals. AmerisourceBergen’s revenues climbed 9.7% in 2018 thanks to overall market growth and brisk sales of expensive cancer drugs. The company’s acquisition of wholesaler H.D. Smith—completed in January of 2018—and the performance of its joint venture with Profarma in Brazil also boosted revenues, as did AmerisourceBergen’s veterinary medicine business. The company is facing issues involving its drug compounding subsidiary PharMEDium and, like its competitors, AmerisourceBergen is under scrutiny for its alleged role in the nation’s opioid crisis.

Company Info

Figures are for fiscal year ended Sept. 30, 2018.
CEO
Steven H. Collis
CEO Title
Chairman, President & Chief Executive Officer
Sector
Health Care
Industry
Wholesalers: Health Care
HQ Location
Chesterbrook, Pa.
Websitehttp://www.amerisourcebergen.com
Years on Fortune 500 List25
Employees20,500
Created with sketchtool.Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Purchase Now

AmerisourceBergen Rank History

placeholder

Key Financials (Last Fiscal Year)

$ millions% change
Revenues ($M)$167,939.69.7%
Profits ($M)$1,658.4355.0%
Assets ($M)$37,669.8-
Total Stockholder Equity ($M)$2,932.8-

Profit Ratios

Profit as % of Revenues1.0%
Profits as % of Assets4.4%
Profits as % of Stockholder Equity56.5%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)7.53
EPS % Change (from 2017)359.1%
EPS % Change (5 year annual rate)32.6%
EPS % Change (10 year annual rate)25.6%

Total Return

Total Return to Investors (2018)-17.6%
Total Return to Investors (5 year, annualized)2.7%
Total Return to Investors (10 year, annualized)17.0%